We do everything we can to plan the doses so that the surrounding tissue is spared," says medical physicist Eva Onjukka, who researches at the Department of Oncology-Pathology at Karolinska ...
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. Exelixis disclosed the ...
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new study. Researchers at Karolinska Institutet have investigated how immune ...
A group of scientists in China has revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage ...
Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous ...
Median PFS improved from 11.5 months with single-agent everolimus to 29.7 months with the addition of lanreotide. Objective responses occurred about three times as often with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback